January 12, 2015 / 12:27 PM / 3 years ago

BUZZ-Tekmira Pharmaceuticals: Acquisition to boost Hep B drugs portfolio

** Canadian biopharmaceutical company’s U.S.-listed shares up 43 pct at $22.40 premarket

** Tekmira to buy OnCore Biopharma Inc to focus on developing hepatitis B virus treatment by combining multiple therapeutic methods

** Implied market value of the merged company is about $750 mln, OnCore shareholders will hold 50 pct of Tekmira

** Tekmira to continue with its oncology and anti-viral programs, including Ebola

** On Sept. 22, the FDA authorized emergency use of Tekmira’s Ebola treatment, but its shares have fallen 33 pct since then through Friday’s close

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below